BioCentury This Week
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Podcasting since 2020 • 366 episodes
BioCentury This Week
Latest Episodes
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts
•
Season 7
•
Episode 356
•
33:59
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on NASDAQ — but will geopolitical tensions and war in the Middle East scuttle the forward momentum...
•
Season 7
•
Episode 355
•
24:40
.png)
Ep. 354 - East-West Summit Takeaways
Biotechs in South Korea and other regions of Asia outside of China need to lean into innovation to distinguish themselves from their Chinese counterparts. On a special edition of the BioCentury This Week podcast, BioCentury’s analysts ...
•
Season 7
•
Episode 354
•
26:21
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
The second ousting of Vinay Prasad from FDA in the past eight months won’t lead to major changes at the agency, other than selecting a successor tasked with keeping FDA out of the news ahead of the coming midterm elections. On the latest Bi...
•
Season 7
•
Episode 353
•
37:04
Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
Can a strong U.S. biopharma industry be reconciled with the successful emergence of China? And can China be a catalyst of positive change across the global industry, even if this implies some level of rebalancing away from the U.S.? On the late...
•
Season 7
•
Episode 352
•
34:42
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.
